News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi to Close Its Research Institute in the UK
To Use Its Know-How in Genomic Drug Discovery in Tsukuba Research Center, Japan

February 19, 2002

Tokyo, Japan -February 19, 2002- Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) has decided to close Yamanouchi Research Institute, Oxford, UK. The closure will be completed at the end of April.

Established in 1990, Yamanouchi Research Institute (UK) has been engaged in basic research focusing on cell biology in close cooperation with Yamanouchi's research center in Tsukuba, Ibaraki Prefecture, Japan, and has achieved a number of important projects. It has established a far-reaching network with universities and other research institutes in Europe and played an important role in Yamanouchi's drug discovery research activities.

In recent years, applications of genome information to research and development of new drugs (genomic drug discovery) have raised keen interest. Global competition in this field is being fuelled as information on genomic sequences increases and gene function analysis progresses rapidly utilizing new information analysis technology such as bioinformatics (post-genome era).

Genomic drug discovery is a critical part of Yamanouchi's drug discovery strategy. It is committed to propelling it even more efficiently and strategically than before by transferring cell biology and other technology developed in the UK to the genomic drug research programs carried out in Tsukuba in order to accelerate the discovery of targets for new drug development through the analysis of gene functions. In the future, Yamanouchi will expand and strengthen its in-house research programs for genomic drug discovery through its research center in Tsukuba. It will also actively undertake strategic alliances with major research centers and bioventure companies in Japan and abroad in order to enhance its competitiveness.